Skip to main content
. 2019 May 23;63(6):e00126-19. doi: 10.1128/AAC.00126-19

FIG 1.

FIG 1

MIC frequency of 19 P. aeruginosa clinical isolates (non-MBL producing and MBL producing) in incremental fosfomycin MICs in monotherapy and in combination therapy with meropenem and the probability of target attainment of an fAUC/MIC of ≥40.8 for fosfomycin dosing regimens. PTA, probability of target attainment; AUC, area under the concentration-time curve; CLCR, creatinine clearance; black bars, fosfomycin MICs for monotherapy; gray bars, fosfomycin MICs for combination therapy. The fosfomycin dosing regimens are represented by lines and symbols, as follows: for CLCRs of >40 ml/min, ▲, 4 g q8h; ●, 4 g q6h; ■, 6 g q8h; +, 8 g q8h; for CLCRs of 20 to 40 ml/min, ▲, 2.8 g q8h; ●, 2.8 g q6h; ■, 4.2 g q8h; +, 5.6 g q8h; for CLCRs of 10 to <20 ml/min, ▲, 2 g q8h; ●, 2 g q6h; ■, 3 g q8h; +, 4 g q8h; for CLCRs of <10 ml/min, ▲, 1.2 g q8h; ●, 1.2 g q6h; ■, 1.8 g q8h; +, 2.4 g q8h.